From the 10-Q:
"As of March 31, 1997, ChemTrak had an accumulated deficit of
approximately $37,603,000. The ability of the Company to achieve profitability
is highly dependent upon numerous factors including, but not limited to, the
Company's ability to directly market and distribute its cholesterol, H. Pylori,
and colorectal products in the United States, successful completion of the
Company's regulatory approval process to market products under development, and
the Company's ability to provide product in sufficient, cost effective
quantities. Due to the uncertainty of these factors, it is difficult to reliably
predict when such profitability may occur, if at all. Until such time as it
achieves profitability, the Company is likely to require additional capital to
finance its operations.
The development and marketing of consumer medical devices is capital
intensive. The Company has funded its operations to date through product sales
and public and private equity and debt financings. The Company will require
substantial additional funding in order to complete the development and
marketing activities in which it is currently engaging, and to launch these
products in the consumer marketplace. The Company intends to seek additional
funding through collaborative agreements with corporate partners or through
additional equity or debt financings. There can be no assurance that the Company
will be able to enter into such arrangements on acceptable terms, or at all."
Hi R-Man, can you help them?
Amots |
